Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome
NCT01882543Phase 2Completed
- Sponsor
- Aquinox Pharmaceuticals
- Start
- Jun 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of rosiglitazone in interstitial cystitis (IC) and bladder pain syndrome (BPS) (2 arms), sponsored by Aquinox Pharmaceuticals. Primary endpoint: Change From Baseline in the Average Daily Bladder Pain Score (e-Diary) at 6 weeks. Started Jun 2013; status: completed.
02
Drugs
rosiglitazone
03
Conditions
interstitial cystitis (IC)bladder pain syndrome (BPS)
Beyond the preview
Go deeper on NCT01882543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01882543.